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Background: Fatty acids in breast-milk such as docosahexaenoic acid and arachidonic acid, commonly known as DHA
and ARA, contribute to the healthy development of children in various ways. However, the manufactured versions that
are added to infant formula might not have the same health benefits as those in breast-milk. There is evidence that the
manufactured additives might cause harm to infants’ health, and they might lead to unwarranted increases in the cost
of infant formula.
The addition of such fatty acids to infant formula needs to be regulated. In the U.S., the Food and Drug Administration
has primary responsibility for regulating the composition of infant formula. The central purpose of this study is to
assess the FDA’s efforts with regard to the regulation of fatty acids in infant formula.
Methods: This study is based on critical analysis of policies and practices described in publicly available documents of
the FDA, the manufacturers of fatty acids, and other relevant organizations. The broad framework for this work was set
out by the author in his book on Regulating Infant Formula, published in 2011.
Results: The FDA does not assess the safety or the health impacts of fatty acid additives to infant formula before they
are marketed, and there is no systematic assessment after marketing is underway. Rather than making its own
independent assessments, the FDA accepts the manufacturers’ claims regarding their products’ safety and effectiveness.
Conclusions: The FDA is not adequately regulating the use of fatty acid additives to infant formula. This results in
exposure of infants to potential risks. Adverse reactions are already on record. Also, the additives have led to increasing
costs of infant formula despite the lack of proven benefits to normal, full term infants. There is a need for more
effective regulation of DHA and ARA additives to infant formula.
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Fatty acids are important components of breast-milk,
contributing to the healthy development of children in
various ways. Most infant formula manufacturers now
add manufactured docosahexaenoic acid and arachidonic
acid, commonly known as DHA and ARA. They are
manufactured in the sense that they are created through
industrial processes, and not created naturally in human
breastmilk. Concerns were raised about these additives
as early as 1996 [1], but they remain unresolved. New
issues are becoming visible as it is recognized that
infant formula is becoming a global commodity, one
that requires coherent global regulation.Correspondence: kent@hawaii.edu
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reproduction in any medium, provided the orThis analysis begins with an overview of the regulatory
agencies at national, regional, and global levels. That is
followed with a discussion of major problematic issues
relating to fatty acids added to infant formula. This then
leads to a call for more systematic regulation of infant
formula in the U.S. and worldwide.
Most binding regulations relating to infant formula
come from national governments, and apply within their
jurisdictions. Typically they are administered through
the nation’s ministry or department of health. In the
U.S., primary responsibility for implementation of the
rules relating to infant formula is lodged with the Food
and Drug Administration (FDA), in the U.S. Department
of Health and Human Services. In large countries, sub-
national layers of government may have some authority
to issue binding regulations relating to infant formula.s is an open access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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regulations relating to infant formula, such as Food Stan-
dards Australia New Zealand (FSANZ). In Europe, the
European Food Safety Authority (EFSA) works on risk as-
sessment, while the European Commission issues Direc-
tives and Regulations. The member countries are asked to
implement the Directives through their national law. The
Common Market of the South, MERCOSUR, in Latin
America, works to harmonize its members’ national legisla-
tion relating to nutrition, but its recent regulation on nutri-
tion claims excludes infant formula from its coverage [2].
The nations of the world have not given any global
agency the authority to issue binding regulations relating
to food, so global agencies are limited to issuing recom-
mendations. The major global inter-governmental agency
issuing recommendations relating to food is the Codex
Alimentarius Commission, organized jointly by the Food
and Agriculture Organization of the United Nations
(FAO) and the World Health Organization (WHO). Apart
from FAO and WHO, several other agencies are con-
cerned with food issues, such as the United Nations Chil-
dren’s Fund (UNICEF) and the World Food Programme
(WFP). However, at the global level, only the Codex
Alimentarius Commission issues detailed technical rec-
ommendations about how national and regional bodies
should regulate in relation to food issues.
The World Trade Organization (WTO) plays an im-
portant role in regulating foods in international trade. It
normally accepts the recommendations of the Codex
Alimentarius Commission with regard to food issues,
especially in its dispute settlement procedures. For na-
tions that are interested in trading their food products
internationally, this often has the effect of turning Codex
recommendations into binding regulations, even though
they do not have that formal legal status. The WTO also
accepts consensus-based standards from other international
organizations, such as the International Organization for
Standardization (ISO).
Several non-governmental organizations play import-
ant roles relating to the regulation of infant formula. For
example, the International Baby Food Action Network,
together with its national branches, urges national gov-
ernments to implement the International Code of Mar-
keting of Breast-milk Substitutes.
There are lobbying groups for the food industry that
can influence regulations, including specialized agencies
such as the Infant Formula Council based in the U.S.,
the Infant Nutrition Council based in Australia, and the
International Association of Infant Food Manufacturers,
based in Switzerland. The major manufacturers of infant
formula and of important ingredients and additives also
lobby the regulatory agencies directly.
The Switzerland-based International Organization for
Standardization and AOAC International “have agreedto cooperate on the development of infant formula and
adult nutritional related standards [3].” AOAC is the
Association of Analytical Communities.
The U.S. Pharmacopeia Convention (USP) is a non-
governmental organization that recommends scientific
standards for pharmaceuticals, foods, and other prod-
ucts. Its food-related recommendations are published
regularly in its Food Chemicals Codex. The FCC was ori-
ginally launched by the National Academy of Sciences,
but transferred over to the USP in 2006. The USP works
only with issues such as the identity and the purity of in-
gredients. It does not consider their functions in terms
of effects on health.
There is effort at self-regulation and consumer educa-
tion by an association of manufacturers of the additives
through the non-governmental Global Organization for
EPA and DHA Omega-3s [4].
The global standard for infant formula established by
the Codex Alimentarius Commission is designated as
CODEX STAN 72–1981. It includes a list of required in-
gredients and names various required quality control
measures [5].
Section 3.2 of this standard, on Optional Ingredients,
says:
3.2.1 In addition to the compositional requirements
listed under 3.1.3, other ingredients may be added in
order to provide substances ordinarily found in
human milk and to ensure that the formulation is
suitable as the sole source of nutrition for the infant
or to provide other benefits that are similar to
outcomes of populations of breastfed babies.
3.2.2 The suitability for the particular nutritional uses of
infants and the safety of these substances shall be
scientifically demonstrated. The formula shall contain
sufficient amounts of these substances to achieve the
intended effect, taking into account levels in human milk.
Brief technical specifications are then provided for a
variety of optional ingredients, including DHA.
In this Codex standard on infant formula, DHA is
regarded as an optional ingredient, not as a food addi-
tive, but some national regulatory agencies describe it as
an additive.
Recommendations from the Codex Alimentarius Com-
mission may be adopted by regional bodies and by na-
tional governments in various ways. In the U.S., they are
codified under U.S. law, and their implementation is
overseen primarily by the U.S. Food and Drug Adminis-
tration. While the FDA has primary responsibility for
the composition of infant formula, the Federal Trade
Commission (FTC) plays an important role in relation
to marketing of the product. The FDA is a regulatory
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FTC investigates and assesses advertising claims.
The Federal Food, Drug, and Cosmetic Act defines in-
fant formula in Title 21, Section 321(z) of the United
States Code of Federal Regulations. It is “a food that pur-
ports to be or is represented for special dietary use solely
as a food for infants by reason of its simulation of hu-
man milk or its suitability as a complete or partial sub-
stitute for human milk (21 U.S. Code 321 (z)).”
Section 350a of the act sets out a list of required nutri-
ents and their minimum and maximum quantities. The
list includes protein, fat, essential fatty acids (only linole-
ate is in the list), fifteen different vitamins, and eleven
different minerals. The list conforms to the recommen-
dations of the Codex Alimentarius Commission.
The U.S. Code of Federal Regulations Title 21, Part
106 specifies infant formula quality control procedures.
It is mainly about quality control during the manufactur-
ing process, and not directly about the quality of the
product that emerges from that process (U.S. Code of
Federal Regulations (21CFR106), 2009). Part 107 states
the nutrient requirements and other rules regarding la-
beling, recalls, etc. [6].
There are four major areas in which regulations relat-
ing to infant formula can be useful: nutrient content,
health claims, safety, and economic value, discussed in
the following four sections of this paper. Nutrient claims
are about ensuring that the manufacturers make clear
and accurate claims about what is in the product. Health
claims are about specific anticipated health benefits, and
whether use of the product does in fact lead to the health
benefits that are claimed. Safety is about whether disease
or death is likely to result from using the product, espe-
cially in the short term. The concern regarding economic
value is about whether the producers make claims that
are misleading in order to enhance their economic gain.
The FDA defines “safe” as “a reasonable certainty in
the minds of competent scientists that the substance is
not harmful under the intended conditions of use”, as
specified in the U.S. Code of Federal Regulations at (21
CFR 170.3(i)).
Safety is about harms that would make you worse off
than if you had not ingested the substance. Concerns
about health impacts usually focus on whether you are
better off as a result of ingesting the substance.
Some studies described the absence of anticipated
health benefits as a safety issue, but most distinguish the
two as different types of quality issues. Failure of infants
who use a particular type of infant formula to achieve
anticipated weight gains, for example [7], usually would
be regarded as a failure to achieve an anticipated health
benefit, not as a safety issue.
This study is based on critical analysis of policies and
practices described in publicly available documents ofthe FDA, the manufacturers of fatty acids, and other
relevant organizations. The broad framework for this
work was set out by the author in his book on Regulat-
ing Infant Formula, published in 2011 [8].
Results and discussion
Claims regarding nutrient content
In the U.S., the Nutrition Labeling and Education Act of
1990, which amended the Food, Drug, and Cosmetic
Act, makes a distinction between nutrient content claims
and health claims. Nutrient content claims characterize
a nutrient in a food. The product should include what
it is claimed to include. Health claims characterize a re-
lationship of a nutrient to a disease or health-related
condition. Health claims are discussed in the following
section.
From time to time the FDA questions manufacturers
regarding their nutrient content claims. To illustrate, a
warning letter from the FDA listed some of one com-
pany’s products and said:
We have concluded that these products are in violation
of the Federal Food, Drug, and Cosmetic Act (the Act)
and FDA regulations. . . . because their labeling includes
unauthorized nutrient content claims. Except for claims
regarding percentages of vitamins and minerals for
which there is an established Reference Daily Intake,
a nutrient content claim cannot be made for a food that
is intended for use by infants and children less than two
years of age unless the claim is specifically provided for
in parts 101, 105, or 107 of the regulations. 21 CFR
101.13(b)(3). . . .
The circumstances under which these claims are
permitted are defined in 21 CFR 101.60(c) and 101.54
(e), respectively. However, those regulations do not
permit these claims for products intended for infants
and children under age 2 [9].
The legal status of manufacturers’ claims regarding the
DHA and ARA content in infant formula have not been
closely examined by the U.S. government. Some of the
current claims might violate the law cited in the FDA’s letter.
There may be other nutrient content concerns about
infant formula and additives to it, such as whether they
are organic or genetically engineered, whether they are
kosher, and whether they are halal. There are few well-
developed regulations regarding these issues.
Some DHA and ARA additives, made on an industrial
scale from fungi or algae, are claimed to be organic
while others dispute that claim [10,11]. There has been
debate over whether additives such as manufactured
DHA and ARA that are made with solvent extraction
processes can be classified as organic [12]. Some parties
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fish, algae, or eggs is organic, while others say taking
such products through an industrial process disqualifies
them from that category. The FDA made a statement on
the issue that did not clarify the matter [13].
Claims regarding health
What evidence for what health claims?
When DHA was first added to infant formula, the pitch
to investors was that the product “may help close gaps
researchers have found between the development of
breast-fed and bottle-fed infants [14].” However, most of
the research on DHA and ARA additives focuses on
comparing infant formulas with different additives. Little
of the research looks into how infant formulas with and
without DHA compare with breastfeeding in terms of
health effects. It might be that infant formula with DHA
produces somewhat better results than infant formula
without that additive, but if both produce far worse re-
sults than breastfeeding, that would be important to
know. Parents need to make well informed choices not
only in deciding which infant formula to use but also in
deciding whether to use formula rather than breastfeed.
Using newer versions of the additive might have better
health effects than older versions, and thus bring the prod-
uct somewhat closer to the performance of breastfeeding.
However, claiming that any infant formula with the fatty
acid is “closest to human milk” or “as close as possible to
human milk” is not the same as saying it is close to human
milk. The claim may be misleading if the difference be-
tween “closer to” and “close to” escapes people’s notice.
When the manufacturers make claims about the health
effects of their DHA and ARA that are added to infant
formula, they pick out studies that support their views,
and ignore studies that do not. They do not clearly iden-
tify the specific studies that supposedly support their
specific claims. There is no clear consensus about what
indicators should be used for the major claims.
To illustrate, one manufacturer’s website said:
Certain studies have also shown that infants fed
formula supplemented with DHA and ARA exhibited:
 Improved mental development
 Better visual acuity
 Significantly lower blood pressure at age six which
may reduce the risk of cardiovascular disease later
in life
Preterm infants who were fed DHA and ARA supple-
mented formula exhibited normal growth in terms of
weight, length and head circumference and improved
visual and mental development [15].
The manufacturer listed 28 studies said to be “Research
Supporting the Importance of DHA & ARA in InfantDevelopment,” with an additional seven listed as
“Research Supporting the Importance of DHA for Pre-
term and Near-term Infants.” It is not clear which of the
studies is supposed to support which of the specific
claims. Many were published prior to 2000, and thus have
little relevance to current versions of manufactured DHA
and ARA. Many of the studies listed have no relevance to
any of the claims.
The list did not mention the many studies that found
no significant health benefit from fatty acids added to in-
fant formula. It did not mention that several major
meta-analyses found no significant effect [16-18].
(The article by Qawasmi and colleagues published on-
line by Pediatrics in June 2012 [16], concluded, “LCPUFA
supplementation of infant formulas failed to show any sig-
nificant effect on improving early infant cognition”. It was
followed by another online article with a similar title in
December 2012, this time concluding, “Current evidence
suggests that LCPUFA supplementation of infant formulas
improves infants’ visual acuity up to 12 months of age.”
The journal published my letter inquiring about the
reasons for this change, but there has been no reply. Their
second article and my letter are available at http://
pediatrics.aappublications.org/content/early/2012/12/12/
peds.2012-0517.abstract/reply#pediatrics_el_54993. A third
and final version of the article appeared in print in
Pediatrics in January 2013, described at http://www.ncbi.
nlm.nih.gov/pubmed/23248232. Its conclusion was the
same as that in the December 2012 version. Apparently,
seven studies were added to the set of twelve originally
reviewed, leading to the change in the conclusion.)
The manufacturer said only that “certain studies”
showed the effects that were claimed, but they did not
specify which ones. There are also studies that fail to
show those effects. The manufacturer has not demon-
strated that the dominant trend in the relevant studies
supports their claims.
Another page on the same website discussed “The
Benefits of DHA and ARA During Infancy” under vari-
ous categories: cognition, vision, immune response, etc.
For each category, the document said there were studies
that supported their claims regarding these benefits. At
the end there was a link to an obscure list of references,
with no indication of which were supposed to support
which claims [19].
The manufacturer said, “Clinical studies have demon-
strated numerous benefits for infants receiving DHA
and ARA supplemented formula, including improved
mental and visual development [20-22],” but it did not
say which studies.
The manufacturer did not say which, if any, of the
studies it listed were specifically about its currently fea-
tured product, trademarked as life’s DHA. For advertis-
ing purposes the manufacturer apparently wants life’s
Kent International Breastfeeding Journal 2014, 9:2 Page 5 of 10
http://www.internationalbreastfeedingjournal.com/content/9/1/2DHA to be viewed as very different from earlier versions
of the manufactured fatty acid, but at the same time it
suggests that earlier research based on other versions of
DHA and the regulations on them should apply just as
well to this latest version [23].
There is no consensus as to what indicators would be
appropriate for assessing each of the different types of
health claims made for fatty acids added to infant for-
mula. Questions have been raised about the Bayley
Scales of Infant Development (BSID) used in the meta-
analysis by Qawasmi and colleagues, and in many other
studies as well [16,24]. The critics argue that these
scales, used primarily for children up to 18 months of
age, are not appropriate for assessing how these in-
gredients affect physical and mental development in
the long run.
The FDA has expressed its doubts about manufac-
turers’ health claims:
16. What is the evidence that addition of DHA and
ARA to infant formulas is beneficial?
The scientific evidence is mixed. Some studies in
infants suggest that including these fatty acids in
infant formulas may have positive effects on visual
function and neural development over the short term.
Other studies in infants do not confirm these benefits.
There are no currently available published reports
from clinical studies that address whether any long-
term beneficial effects exist [25].
Which DHA?
When a manufacturer listed “Research Supporting the
Importance of DHA & ARA in Infant Development,” it
did not say all these studies would show the importance
of manufactured DHA and ARA. The manufacturer
implicitly assumed that evidence relating to human
DHA and ARA as found in breast-milk would apply just
as well to their manufactured versions. However, the
manufacturer’s claims were specifically about “formula
supplemented with DHA and ARA,” meaning the manu-
factured versions.
DHA in breast-milk tested in a chemistry laboratory
might appear to be similar to a manufactured DHA. How-
ever, the real test of equivalence is whether they function
in the same way. Do they lead to the same results for in-
fants on relevant health indicators? The health effect of the
two should not be claimed to be the same unless their
performance is demonstrated to be the same [26].
It is also important to distinguish among various types
of manufactured DHA. U.S. Pharmacopeia’s Food Chemi-
cals Codex distinguish three types of algae-based DHA,
corresponding to three different algal oils: schizochytrium,
crypthecodinium, and ulkenia.There are other DHAs that are not in the Food Chemicals
Codex. For example, there is an egg-based DHA:
Baby’s Only Essentials® DHA & ARA Fatty Acid is
naturally derived from the goodness of Egg
Phospholipids using an aqueous (water) process. This
differs from C. cohnii oil (algae) & M. alpina oil
(fungus) used in all other organic and conventional
infant formulas, which are treated with hexane
solvent, acid, and bleach [27].
It is not clear how the different types of manufactured
DHA compare with regard to their safety or their effect-
iveness. If the newer ones are said to be improvements,
that implicitly acknowledges that the earlier ones must
have been deficient.
Regulations regarding health claims
U.S. rules regarding health claims have been summarized
as follows:
. . . . the Nutrition Labeling and Education Act . . . .
set a high threshold for the scientific standard under
which the U.S. Food and Drug Administration (FDA)
may authorize health claims, this standard is known
as the significant scientific agreement (SSA) standard.
Subsequent legislation known as the Food and Drug
Administration Modernization Act (FDAMA)
provided an alternative to FDA review of the health
claim where an U.S. government scientific body other
than FDA concluded that there is SSA for a
substance/disease relationship ([28], also see [29]).
Comparable regulations of health claims came into
force for the European Union in January 2007 [30].
Following the practice in a number of other countries,
in 2001 the FDA accepted the addition of manufactured
DHA to infant formulas. However, the agency has not
affirmed that this addition is beneficial, and it has not
explicitly authorized the manufacturers to make claims
regarding their benefits.
The FDA explains its role as follows:
4. Does FDA approve infant formulas before they
are marketed?
No, FDA does not approve infant formulas before
they can be marketed. However, all formulas
marketed in the United States must meet federal
nutrient requirements and infant formula
manufacturers must notify the FDA prior to
marketing a new formula. If an infant formula
manufacturer does not provide the elements and
assurances required in the notification for a new or
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adulterated under Section 412(a)(1) of the FFDCA and
FDA has the authority to take compliance action if the
new infant formula is marketed ([25], also see [31]).From time to time FDA responds to petitions regard-
ing health claims. There is a good illustration of how
such petitions are handled in FDA’s response to a peti-
tion regarding a health claim for whey-protein partially
hydrolyzed infant formula [32].
The FDA has not endorsed the manufacturers’ claims
regarding the health benefits of adding DHA to infant for-
mula. It may authorize health claims, under the standard
known as significant scientific agreement (SSA). The law
does not say the FDA must authorize health claims. There
is no published SSA for DHA in infant formula [33].
The Infant Formula Council, a lobbying group for the
manufacturers, said, “The use of LCPUFAs [long chain
polyunsaturated fatty acids] in infant formulas has been
reviewed and supported by the U.S. Food and Drug Ad-
ministration [34].” Given FDA’s explanation that it does
not approve infant formula and its statement that the
evidence regarding the benefits of DHA and ARA in in-
fant formula is mixed, it is difficult to guess what the
Council might have meant by “reviewed and supported.”
There is little effective regulation with regard to health
claims or the general nutritional adequacy of infant for-
mula and its additives. The regulators regularly accept
the manufacturers’ claims that the currently proposed
versions are superior, but do not explore how the previ-
ous ones might have been deficient.
Current regulations for infant formula focus on ensur-
ing that particular components are supplied in specified
quantities, based on an ingredients list from the 1980s.
They imply that any formula that includes the specified
ingredients in the required amounts is safe and nutri-
tionally adequate. However, breast-milk is a complex,
changing, living thing, and not simply a static collection
of inert ingredients. Many ingredients in breast-milk are
absent in infant formula, or are provided in infant formula
in forms that are different from those in breast-milk.
There is little recognition of the fact that ingredients can
act differently in different contexts.
It should not be assumed that DHA additives that are
manufactured by one process have the same health ef-
fects as DHA manufactured by another process. Simi-
larly, it should not be assumed that the health effects of
manufactured DHA in infant formula are the same as
the health effects of natural DHA in breast-milk. These
propositions need to be verified empirically.
Claims regarding safety
The FDA’s treatment of additives is different from its ap-
proach to food in general. Its position is that “companiesthat want to add new additives to food bear the responsi-
bility of providing FDA with information demonstrating
that the additives are safe. FDA experts review the results
of appropriate tests done by companies to ensure that the
additive is safe for its intended use. . . . Certain food ingre-
dients, such as those with a long history of safe use in
food, do not require premarket approval [31].”
GRAS determination
The FDA’s Guidelines Concerning Notification and Testing
of Infant Formulas say:
A manufacturer must notify FDA 90 days before the
first processing of any infant formula for commercial
or charitable distribution for human consumption
that differs fundamentally in processing or in
composition from any previous formulation produced
by the manufacturer [35].
These incremental changes are handled by determin-
ing whether the proposed additives are GRAS, Generally
Regarded as Safe. It is not the FDA itself that assesses
their safety. The manufacturer is supposed to assess
their safety and notify the FDA of its findings. To illus-
trate, in 2001 the FDA responded to requests from man-
ufacturers to have their versions of these fatty acids,
ARASCO and DHASCO, characterized as GRAS. In its
response, the FDA said:
The agency has not, however, made its own
determination regarding the GRAS status of the
subject use of ARASCO and DHASCO [36].
The FDA had no questions about the documents sub-
mitted to it about the companies’ requests for GRAS
status for these products, and it acknowledged that the
FDA had not made its own independent determination
regarding their status. The FDA did not say whether it
agreed with the requests.
The FDA’s Inventory of GRAS Notices shows that the
agency records the details of the notifications regarding
GRAS that it receives [37]. The FDA does not affirm
that the product is safe.
The GRAS determination process is explained in
FDA’s Frequently Asked Questions about GRAS [38]. The
answer to question 10 is of particular interest:
Does FDA currently have a program to affirm that
one or more uses of a food substance are GRAS?
In a proposed rule that FDA published in 1997
(62 Fed. Reg. 18938; April 17, 1997), FDA explained
why the agency could no longer devote resources to
the voluntary GRAS affirmation petition process that
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abolish that process and replace it with a notification
procedure. The agency has not yet issued a final rule
however, and the petition procedure remains in the
agency’s regulations. However, at this time FDA is not
committing resources to the review of GRAS
affirmation petitions.
In other words, the FDA does not evaluate the GRAS
petitions it receives.
The question is not whether these optional ingredients
are in fact safe to use. The GRAS question is about
whether they can reasonably be assumed to be safe. The
distinction is important. To illustrate, one could be un-
sure whether infant formula made with genetically modi-
fied soy is safe for infants, but at the same time be
certain that it should not be assumed to be safe.
The GRAS concept was developed to avoid having to sci-
entifically assess familiar products that were known to be
safe on the basis of extensive experience in diverse condi-
tions. In the case of novel products such as manufactured
DHA and ARA intended for highly vulnerable infants, the
designation seems unreasonable. Moreover, depending on
the manufacturers of the products to make the judgment
about whether the product should be considered GRAS
seems unreasonable. Children should not be made to bear
the risk entailed in making that assumption.
Postmarket surveillance
The FDA’s acceptance of the GRAS notification allows
manufacturers to begin marketing the product. However,
in its letters to the manufacturers, the FDA said:
FDA would expect any infant formula manufacturer
who lawfully markets infant formula containing
ARASCO and DHASCO to monitor, through
scientific studies and rigorous post-market surveil-
lance, infants who consume such a formula. We also
would expect regular reports of such studies and post-
market surveillance. Because the use of ARASCO and
DHASCO in infant formula would be based on the
GRAS provision of the FFDCA, we also would expect
that these reports would not be considered to be con-
fidential so that the broader scientific community can
contribute to this continuing evaluation [36,39].
Thus, there was an expectation of surveillance of the
products’ safety and health effects after marketing was
underway.
In response to an inquiry from the Cornucopia Insti-
tute in 2009, the FDA said it had received no postmarket
surveillance reports on the safety and effectiveness of
these products. Nevertheless, the industry proceeded
with large-scale advertising campaigns promoting infantformula and many other food products based on its
claims about the benefits of these additives [40]. There is
no indication that the manufacturer has ever done such
studies [10,41].
Numerous “Adverse Reaction Reports” that appear to
be related to DHA/ARA in infant formula have been
submitted to the FDA. The Cornucopia Institute has
made some of them available on its website [42]. The
adverse reactions described by mothers included gas,
diarrhea, vomiting, bowel obstruction, gastric reflux,
colic, and constipation.
It is unfortunate that FDA relies on the industry for
post-market surveillance of the effects of optional ingre-
dients because the value of the industry’s reports would
be highly questionable. It is even more problematic that
the FDA now seems to be indifferent to the failure of
the industry to conduct such studies.
Concerns relating to economic values
Safety refers to possible harm to health, but there is also
the possibility of economic harm. The risk is high, given
the strong economic motivations of those who promote
infant formula and additives to it. It appears that several
infant formula manufacturers add various ingredients,
make dubious claims about their health benefits, and in-
crease their products’ prices in order to draw economic
benefits from those claims. Several manufacturers put
out specialized infant formulas with prices that are con-
siderably higher than the generic “store brands”. There
might be some truth to the health claims, but reasons to
doubt whether they are sufficient to justify their in-
creased economic costs.
This pattern is evident in relation to the addition of
DHA and ARA to infant formula. In the 1990s, a stock
promotion said:
Infant formula is currently a commodity market, with
all products being almost identical and marketers
competing intensely to differentiate their product.
Even if Formulaid had no benefit, we think that it
would be widely incorporated into most formulas, as
a marketing tool and to allow companies to promote
their formula as ‘closest to human milk’ [43].
The infant formula business is lucrative because the
profits per unit are high, and also because huge growth
is anticipated, especially in Asia. Additives tend to in-
crease the already high profit margins.
Since the economic incentives are so strong, new
additives may be promoted without sufficient regard
for their effect on infants’ health. Some additives ap-
pear to be designed to exploit parents’ willingness to
pay higher prices to gain every possible benefit for
their children.
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the addition of fatty acids to infant formula is not large.
But that cost adds up quickly for private or public agen-
cies that purchase large quantities of the product. The big-
gest purchaser is the United States’ Special Supplemental
Program for Women, Infants and Nutrition, commonly
known as WIC. That program supplies about half the in-
fant formula used in the U.S., at no cost to the families.
According to the nongovernmental Center on Budget &
Policy Priorities, “WIC appears to be spending more than
$90 million extra annually—or more than 10 percent of its
total spending on infant formula—to provide formulas
with ingredients that neither USDA nor the FDA has
assessed with regard to their benefits [44,45].”
Despite its responsibilities as an agency of the U.S.
government, WIC does not have the power to prevent
this. As explained by Maureen Minchin:
A 2004 legislative change removed WIC’s ability to
determine which of the formulas it wanted from a
tendering company; companies could determine what
formula they offered to WIC, at what price. If they
offered the expensive or novel brands, WIC had no
choice but to become the inadvertent marketer of
such products, despite the lack of scientific proof of
either safety or efficacy, or the preferences of the WIC
authority. Attempts as late as 2010 to study the new
ingredients were stymied by high-powered industry
lobbyists . . . [46].
This has major consequences because many women
both in and out of the WIC program view WIC’s provid-
ing particular types of infant formula as indicating gov-
ernment endorsement of them.
In the U.S., the Federal Trade Commission has primary
responsibility for issuing cautions and regulations relating
to commerce. In 2010 it sent letters to eleven companies
that promote fatty acid supplements in infant food, asking
them to “review their product packaging and labeling to
make sure they do not violate federal law by making base-
less claims about how the supplements benefit children’s
brain and vision function and development [47].”
A few months later, the FTC issued an order settling
charges that certain manufacturers had made false and
unsupported claims that their children’s multivitamins
contained a significant amount of DHA and promoted
healthy brain and eye development. The companies
agreed to pay $2.1 million to provide refunds to con-
sumers [48]. Perhaps the FTC should examine question-
able claims related to fatty acids in infant formula.
Conclusions
Infant formula is sometimes regarded as a standardized
commodity, with any product that meets the legalspecifications presumed to be as good as any other.
When the basic recipe was worked out in the 1980s, the
argument was that it would be fully adequate for all nor-
mal children. However, product differentiation by
brands, advertising, and the stream of various optional
ingredients and additives imply that some versions of in-
fant formula are superior. This means others are inferior.
This raises serious questions about whether the basic re-
cipe for infant formula really is nutritionally adequate.
It is impossible for parents to scientifically judge the
validity of the various health claims regarding infant for-
mula. No independent agency compares different infant
formula products. If an additive can be clearly shown to
be beneficial for infants in the general population, with-
out simultaneously resulting in significant harm, it
should be added to the basic list of required ingredients
for infant formula. Rather than regard such ingredients
as optional and possibly available only to high-income
families, all formula-fed infants should get them. Good
research would have to be done to determine that a pro-
posed new component should be required in all infant
formula.
Exceptions could be made for infants with particu-
lar needs. DHA and ARA additives might be appro-
priate for some infants, but not for the great majority
of them. Formulas for infants with particular needs
could be defined as pharmaceuticals, and distributed
on a prescription basis, rather than through commer-
cial marketing.
Another option would be to categorize some of the
optional ingredients and additives as medical foods.
According to the FDA,
The term medical food, as defined in Section 5(b) of
the Orphan Drug Act (21 U.S.C. 360ee (b) (3)) is “a
food which is formulated to be consumed or
administered enterally under the supervision of a
physician and which is intended for the specific
dietary management of a disease or condition for
which distinctive nutritional requirements, based on
recognized scientific principles, are established by
medical evaluation [49].”
This approach would encourage more thorough govern-
mental monitoring of optional ingredients and additives.
Many of the issues raised here regarding fatty acids in
infant formula may be relevant to other additives, such
as prebiotics and probiotics [50-53], nucleotides [54],
and sweeteners [55]. Some additives might have un-
proven benefits, be unnecessarily costly, or expose in-
fants to new kinds of harms. Comparable issues arise
not only for optional ingredients and additives, but also
for other types of infant formula, such as soy-based in-
fant formula.
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the quality of infant formula and related optional in-
gredients and additives are not adequately regulated
to ensure that the interests of children and their fam-
ilies are protected. Infants are exposed to potential
risks that have not been adequately assessed. Also,
the additives lead to increasing costs of infant for-
mula despite the lack of proven benefits to normal,
full term infants.
Contrary to many people’s assumptions and expectations:
1. The U.S. Food and Drug Administration does not
systematically assess health claims related to infant
formula or to specific additives such as fatty acids.
2. The U.S. Food and Drug Administration does not
systematically assess the safety of infant formula or
to specific additives such as fatty acids.
3. The U.S. Food and Drug Administration does not
systematically evaluate the manufacturers’ claims
regarding safety and health for infant formula or
specific additives such as fatty acids.
4. There is no independent systematic field research on
health claims or safety related to infant formula or
specific additives such as fatty acids.
This pattern raises questions about whether govern-
ment agencies in the U.S. are carrying out their obliga-
tions to ensure the safety and nutritional adequacy of
infant formula in its various forms. The same questions
should be raised for every country.
The major infant formula producers operate globally,
and they are planning a massive push into Asia and
other parts of the world. One consultancy firm says, “In
2011 the infant formula market is still growing rapidly,
with the development of markets like Asia, particularly
China, with a growth rate close to 20 % per year, Eastern
Europe, and in a lesser extent Middle East and Latin
America [56].”
Another report says China’s baby food and drink mar-
ket is expected to be worth more than $15 billion by
2015, with perhaps 80 percent of this comprised of in-
fant formula [57].
In this rapid globalization of the infant formula mar-
ket, the fatty acids are going along, as indicated by one
manufacturer’s sole-source supply agreement with Fon-
terra, the world’s largest dairy exporter [58].
With the infant formula industry having enormous
global reach, the model of regulation under separate na-
tional jurisdictions is outdated. The nations of the world
should act together to strengthen quality control for in-
fant formula and other foods intended for children.
There is a need for a global perspective in regulation,
one that is based on appreciation of differences in local
circumstances.Abbreviations
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